Statement Of Income

Oncolys BioPharma Inc. - Filing #7310662

Concept 2024-01-01 to
2024-06-30
2023-01-01 to
2023-06-30
Statement of income
Statement of income
Operating revenue
Net sales
Net sales
31,384,000 JPY
63,038,000 JPY
Cost of sales
Cost of sales
JPY
32,433,000 JPY
Operating expenses
Operating expenses - general
Remuneration for directors (and other officers)
51,291,000 JPY
48,486,000 JPY
Operating expenses
Selling, general and administrative expenses
824,755,000 JPY
931,594,000 JPY
Operating expenses
Research and development expenses
523,975,000 JPY
636,952,000 JPY
Gross profit (loss)
31,384,000 JPY
30,604,000 JPY
Operating profit (loss)
-793,371,000 JPY
-900,989,000 JPY
Ordinary profit (loss)
-752,997,000 JPY
-867,441,000 JPY
Gross profit
General and administrative expenses
Salaries
Non-operating income
Interest income
1,047,000 JPY
533,000 JPY
Non-operating income
Dividend income
5,000 JPY
3,000 JPY
Non-operating income
49,593,000 JPY
35,765,000 JPY
Financial revenue
Other
22,000 JPY
177,000 JPY
Selling, general and administrative expenses
Extraordinary income
JPY
136,000 JPY
Non-operating expenses
Interest expenses
2,185,000 JPY
1,781,000 JPY
Non-operating expenses
Non-operating expenses
9,219,000 JPY
2,217,000 JPY
Financial expenses
Share issuance costs
2,466,000 JPY
JPY
Non-operating expenses
Other
73,000 JPY
JPY
Extraordinary income
Gain on sale of non-current assets
JPY
136,000 JPY
Profit (loss) before income taxes
-752,997,000 JPY
-867,305,000 JPY
Income taxes - current
1,871,000 JPY
1,457,000 JPY
General and administrative expenses
Income taxes
1,871,000 JPY
1,457,000 JPY
Profit (loss)
-754,868,000 JPY
-868,762,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.